UCB snags an NDA-ready epilep­sy drug from Prox­im­a­gen in $370M deal

UCB is beef­ing up its pipeline of epilep­sy drugs with an NDA-ready ther­a­py from Prox­im­a­gen. The Bel­gian com­pa­ny has agreed to buy their nasal spray ther­a­py USL261, de­signed as a res­cue ther­a­py for acute repet­i­tive seizures, for $150 mil­lion in cash and an­oth­er $220 mil­lion in sales and reg­u­la­to­ry mile­stones.

There’s not a lot out there on this drug. UK-based Prox­im­a­gen her­ald­ed a suc­cess­ful Phase III last year, with­out in­clud­ing any da­ta from the piv­otal. And it’s tak­en its web site down at least tem­porar­i­ly for ren­o­va­tions. An­nounc­ing the da­ta last year, the biotech said that it would be fil­ing an NDA be­fore the end of the year, but UCB now says that they’ll be steer­ing the ap­pli­ca­tion to reg­u­la­tors lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER